Menu Search
Equities

Elicera Therapeutics AB

8E8:FRA

Elicera Therapeutics AB

Actions
  • Price (EUR)0.1395
  • Today's Change0.015 / 12.05%
  • Shares traded--
  • 1 Year change-69.47%
  • Beta--
Data delayed at least 15 minutes, as of Nov 06 2024 08:19 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Elicera Therapeutics AB is a Sweden-based clinical-stage immuno-oncology company. The Company is developing next-generation cell and gene therapies for immune-based treatment of cancer. The company is developing four drug candidates, two of which are in the field of oncolytic viruses and two in the field of CAR T-cell treatments. Elicera also has a fully developed platform technology called iTANK (ImmunoTherapies Activated with Nap for efficient Killing) for further immune strengthening in treatment in the said field. Elicera has two projects in each field: ELC-100 is an oncolytic virus, also called AdVince, that is in a clinical phase I/II trial, sponsored by Uppsala University, in the treatment of neuroendocrine tumors and ELC-301 is a CAR T-cell therapy in the treatment of B-cell lymphoma, which has been granted support from the Swedish Cancer Society for the planning and implementation of a clinical phase I/II CAR T-cell study.

  • Revenue in SEK (TTM)12.07m
  • Net income in SEK-20.79m
  • Incorporated2014
  • Employees2.00
  • Location
    Elicera Therapeutics ABWorld Trade Center GoteborgMassans gata 10, van 7GOETEBORG 412 51SwedenSWE
  • Websitehttps://www.elicera.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.